DEVELOPMENT OF A TRANSCRIPTOMICALLY-GUIDED THERAPEUTIC STRATEGY THAT COMBINES TARGETED THERAPIES THAT BOTH EFFECTIVELY TREAT GLIOBLASTOMA AND PREVENT THE EMERGENCE OF TREATMENT RESISTANCE

PI and Consortium Leader: Steven Rosenfeld MD, PhD
Professor, Departments of Oncology, Neurology, and Molecular Pharmacology
Deputy Director
Mayo Clinic Comprehensive Cancer Center

Close Menu